

## **Amendments to the Specification**

Please amend the specification as follows:

On page 8 after the paragraph ending on line 24, insert:

--A dose dependent effect was observed with the optimal concentration being 100  $\mu$ M for the uncapped peptide. However, with the capped peptide better migration compared to the uncapped peptide was observed at a 10-fold lower concentration. The respective scramble peptides showed fewer cells migrating. Figure 1C shows the migration of endothelial cells in a modified Boyden chamber assay in response to various treatments. Both IGD and GGIGDGG cause increased migratory response compared to either the negative control of the corresponding scramble peptides.--

On page 9 at line 9, after “See Fig. 2.”, insert:

--It can be seen that with the capped tripeptide the proliferative response was nearly twice as great as that of the uncapped tripeptide. In either case the scramble peptides showed a significantly lower response than the active peptides.--

On page 9 at line 26, after “See Figs. 3A and 3B”, insert:

--Fig. 3A shows data as a percent change over negative control, the negative being set at 100%. It can be seen that the capped peptide was better than the uncapped peptide at equivalent concentrations. As shown in Fig. 3B, the vessel density in 7 day old quail embryos treated with the capped IGD motif (GGIGDGG) resulted in increased vessel density compared to either the carrier alone (povidone) or the scramble peptide (GGDIGGG) treatment.--

Please delete the Sequence Listing on pages 16-17 and replace it with the following paragraph:

--The appended Sequence Listing is incorporated herein by reference.--

Please replace Figures 1A, 1B, 1C, 2, 3A, and 3B with the attached replacement sheets and delete Figures 4, 5, and 6 from the application.